Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative bevacizumab plus CAPOX induction followed by capecitabine chemoradiotherapy in high-risk locally advanced rectal cancer
2010-024354-11Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in rectal cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoints: Termination of therapy and Occurrence of toxicity. Started Jan 2011; status: completed.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2010-024354-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024354-11.